BC Partners, a European private equity firm, acquired a majority stake in Havea from 3i and Cathay Capital. The transaction is structured as a new Leveraged Buy‑Out, with BC Partners XI—the firm’s 11th flagship fund, closed at about EUR 5.3 billion—taking the lead and bringing in co‑investors PSP Investments from Canada and NPS Investment Management from South Korea as minority partners. 3i and Cathay Capital fully exit the position, while the management team led by CEO Nicolas Brodetsky reinvests alongside the new sponsors, aligning incentives for a second turn of value creation. Havea, formerly known as Ponroy Santé, had grown its revenue from a much lower base in 2017 to over EUR 212 million in 2021, with EBITDA rising to above EUR 70 million, driven by a double‑digit organic growth profile and a series of bolt‑on acquisitions that reshaped the group around five flagship brands: Aragan, Biolane, Densmore, Dermovitamina, and Vitavea. The board attributes the deal’s compelling valuation to favorable macro tailwinds in natural health, consumer‑healthcare structuring led by large pharmaceutical groups, and a strong, diversified brand portfolio with clear potential for European expansion.

HAVEA, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the average currently observed in the Retail & Consumer sector (11.0x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.